Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials-Reference-Cited by-同舟云学术

Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials

Published:2018-12-12 Issue:6 Volume:29 Page:1042-1052
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:Modern Rheumatology

Author:

Fitz-Patrick David¹,Roberson Kent²,Niwa Kiyoshi³,Fujimura Takabumi⁴,Mori Koji⁵,Hall Jesse⁶,Yan Xiaohong⁶,Shen Zancong⁶,Liu Sha⁶,Ito Yasushi⁶,Baumgartner Scott⁶

Affiliation:

1. East-West Medical Research Institute, Honolulu, HI, USA;

2. Delta Waves Sleep Disorder & Research Center, Colorado Springs, CO, USA;

3. Niwa Family Clinic, Chofu, Tokyo, Japan;

4. Thinkpark Heart Clinic, Tokyo, Japan;

5. Mori Clinic, Fukuoka, Japan;

6. Ardea Biosciences, Inc., San Diego, CA, USA

Funder

Ardea Biosciences, Inc., a member of the AstraZeneca group

Publisher

Oxford University Press (OUP)

Subject